Alpine Immune Sciences Announces Pricing of $100 Million Public Offering
SEATTLE–(BUSINESS WIRE)–Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the pricing of its underwritten public offering of 13,606,000 shares of its common stock pursuant to its existing shelf registration statement. The shares of common stock are being offered at … [Read more…]
